Safety, Tolerance, PK, and Anti-tumour Activity of AZD1775 Monotherapy in Patients With Advanced Solid Tumours
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Ovarian Cancer, TNBC, SCLC, Other Solid Tumours
Interventions: DRUG: AZD 1775
Sponsor: AstraZeneca